Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Yearly Archives: 2010

First Orally Bioavailable Anti-Obesity/Diabetes Peptide Drug Candidate to be Presented at the Endocrine Society Annual Meeting in San Diego, June 19-22, 2010

SAN DIEGO, CA May 13, 2010 – Data demonstrating the efficacy of the first and only anti-obesity and anti-diabetic peptide drug candidate not requiring injection will be presented at the Endocrine Society Annual Meeting in San Diego, June  19-22, 2010 by Dr. Patricia Grasso. In 2000, researchers at Albany Medical College, in Albany NY, under […]

Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatide -7 day study will provide an initial comparison with Eli Lilly’s Forteo®-

West Conshohocken, PA – (January 28, 2010) – Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC.   Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company’s Forteo […]

Aegis Therapeutics and Dr. Reddy’s Announce Strategic Alliance

JANUARY 25, 2010, HYDERABAD and SAN DIEGO — Dr. Reddy’s Laboratories (NYSE: RDY)  and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Dr. Reddy’s access to Aegis’ Intravail® drug delivery technology for certain undisclosed therapeutics currently being marketed with annual worldwide sales in excess of U.S. $1 billion. Financial terms were not disclosed. Commenting […]